NO20002276D0 - Substituerte anilider - Google Patents

Substituerte anilider

Info

Publication number: NO20002276D0
Authority: NO; Norway
Prior art keywords: compounds; prodrugs; oxides; hydroxy; halogen
Prior art date: 1997-10-31

Application number

NO20002276A

Other languages

English (en)

Other versions

NO20002276L (no

Inventor

Peter Charles Astles

David Edward Clark

Alan John Collis

Paul Joseph Cox

Paul Joseph Eastwood

Neil Victor Harris

Justine Yeun Quai Lai

Andrew David Morley

Barry Porter

Original Assignee

Aventis Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-31

Filing date

2000-04-28

Publication date

2000-04-28

1997-10-31 Priority claimed from GBGB9723072.6A external-priority patent/GB9723072D0/en

1998-07-01 Priority claimed from GBGB9814276.3A external-priority patent/GB9814276D0/en

2000-04-28 Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd

2000-04-28 Publication of NO20002276D0 publication Critical patent/NO20002276D0/no

2000-05-25 Publication of NO20002276L publication Critical patent/NO20002276L/no

Links

229940051881 anilide analgesics and antipyretics Drugs 0.000 title 1
150000003931 anilides Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
150000001204 N-oxides Chemical class 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
102000016359 Fibronectins Human genes 0.000 abstract 1
108010067306 Fibronectins Proteins 0.000 abstract 1
108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
230000003993 interaction Effects 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Circuit Arrangements For Discharge Lamps (AREA)
Liquid Crystal Substances (AREA)

NO20002276A 1997-10-31 2000-04-28 Substituerte anilider NO20002276L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9723072.6A GB9723072D0 (en)	1997-10-31	1997-10-31	Chemical compounds
US6969597P	1997-12-16	1997-12-16
GBGB9814276.3A GB9814276D0 (en)	1998-07-01	1998-07-01	Chemical compounds
US10428798P	1998-10-14	1998-10-14
PCT/GB1998/003294 WO1999023063A1 (en)	1997-10-31	1998-11-02	Substituted anilides

Publications (2)

Publication Number	Publication Date
NO20002276D0 true NO20002276D0 (no)	2000-04-28
NO20002276L NO20002276L (no)	2000-05-25

Family

ID=27451719

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20002276A NO20002276L (no)	1997-10-31	2000-04-28	Substituerte anilider

Country Status (21)

Country	Link
US (1)	US6479519B1 (no)
EP (1)	EP1027328B1 (no)
JP (1)	JP4555468B2 (no)
KR (1)	KR20010031557A (no)
CN (1)	CN1327443A (no)
AT (1)	ATE337298T1 (no)
AU (1)	AU748041B2 (no)
BR (1)	BR9813331A (no)
CA (1)	CA2303848C (no)
DE (1)	DE69835688T2 (no)
DK (1)	DK1027328T3 (no)
ES (1)	ES2268793T3 (no)
HU (1)	HUP0100699A3 (no)
IL (2)	IL135836A0 (no)
NO (1)	NO20002276L (no)
NZ (1)	NZ503407A (no)
PL (1)	PL340261A1 (no)
PT (1)	PT1027328E (no)
SK (1)	SK5462000A3 (no)
TR (1)	TR200001179T2 (no)
WO (1)	WO1999023063A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK9372000A3 (en) *	1997-12-23	2002-03-05	Rhone Poulenc Rorer Ltd	Substituted beta-alanines
HUP0101419A3 (en) *	1998-04-16	2002-08-28	Texas Biotechnology Corp Houst	Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
AU3716499A (en) *	1998-04-21	1999-11-08	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
GB9826174D0 (en) *	1998-11-30	1999-01-20	Celltech Therapeutics Ltd	Chemical compounds
WO2000039103A1 (en) *	1998-12-23	2000-07-06	Aventis Pharma Limited	Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines
EP2298311B1 (en)	1999-01-13	2012-05-09	Bayer HealthCare LLC	w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6291503B1 (en)	1999-01-15	2001-09-18	Bayer Aktiengesellschaft	β-phenylalanine derivatives as integrin antagonists
CA2360740A1 (en)	1999-03-02	2000-09-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cathepsin s
ATE421958T1 (de) *	1999-05-05	2009-02-15	Aventis Pharma Ltd	Substituierte bizyclische verbindungen
US6756378B2 (en)	1999-06-30	2004-06-29	Pharmacopeia Drug Discovery, Inc.	VLA-4 inhibitor compounds
BR0012068A (pt) *	1999-06-30	2002-05-14	Daiichi Seiyaku Co	Compostos inibidores de vla-4
ES2270868T3 (es) *	1999-08-13	2007-04-16	Biogen Idec Ma Inc.	Inhibidores de la adhesion celular.
US6420364B1 (en)	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
YU41202A (sh) *	1999-12-28	2005-03-15	Pfizer Products Inc.	Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
AU2001235806A1 (en) *	2000-03-01	2001-09-12	Aventis Pharma Limited	2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6960597B2 (en)	2000-06-30	2005-11-01	Orth-Mcneil Pharmaceutical, Inc.	Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10111877A1 (de)	2001-03-10	2002-09-12	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de)	2001-08-01	2003-02-13	Aventis Pharma Gmbh	Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
DK1478358T3 (da)	2002-02-11	2013-10-07	Bayer Healthcare Llc	Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2004058722A1 (en) *	2002-12-24	2004-07-15	Arena Pharmaceuticals, Inc.	Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en)	2003-05-20	2012-06-13	Bayer HealthCare LLC	Diaryl ureas with kinase inhibiting activity
NZ544331A (en)	2003-07-22	2010-03-26	Arena Pharm Inc	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
PL1663978T3 (pl)	2003-07-23	2008-04-30	Bayer Healthcare Llc	Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20060004005A1 (en) *	2003-09-25	2006-01-05	Sattigeri Viswajanani J	Triazines derivatives as cell adhesion inhibitors
US20050176755A1 (en) *	2003-10-31	2005-08-11	Dyatkin Alexey B.	Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
CA2555227A1 (en) *	2004-02-10	2005-08-25	Janssen Pharmaceutica, N.V.	Pyridazinone ureas as antagonists of .alpha.4 integrins
KR20070004676A (ko) *	2004-02-10	2007-01-09	얀센 파마슈티카 엔.브이.	알파４ 인테그린의 길항제로서의 피리다지논
CN1926114B (zh) *	2004-03-23	2011-08-24	艾尼纳制药公司	用于制备经取代n-芳基-n′-′3-(1h-吡唑-5-基)苯基脲及其中间体的方法
PE20061130A1 (es) *	2004-11-19	2007-01-05	Arena Pharm Inc	Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
WO2006060762A2 (en) *	2004-12-03	2006-06-08	Arena Pharmaceuticals, Inc.	Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CA2594563A1 (en) *	2005-01-19	2006-07-27	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
EP1961750B1 (en)	2005-12-13	2013-09-18	Daiichi Sankyo Company, Limited	Vla-4 inhibitory drug
EP2027119A2 (en) *	2006-05-18	2009-02-25	Arena Pharmaceuticals, Inc.	Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) *	2006-05-18	2012-04-03	Arena Pharmaceuticals, Inc.	Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ571829A (en)	2006-05-18	2011-10-28	Arena Pharm Inc	Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh)	2006-10-03	2013-11-21	Arena Pharm Inc	用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
AU2008219007A1 (en)	2007-02-20	2008-08-28	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008112164A2 (en)	2007-03-08	2008-09-18	The Board Of Trustees Of The Leland Stanford Junior University	Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
ES2421237T7 (es)	2007-08-15	2013-09-30	Arena Pharmaceuticals, Inc.	Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
WO2009123714A2 (en) *	2008-04-02	2009-10-08	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
JP5639039B2 (ja)	2008-04-11	2014-12-10	メリマックファーマシューティカルズインコーポレーティッド	ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010028175A1 (en)	2008-09-08	2010-03-11	The Board Of Trustees Of The Leland Stanford Junior University	Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9126946B2 (en)	2008-10-28	2015-09-08	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
TR201805216T4 (en)	2008-10-28	2018-06-21	Arena Pharm Inc	COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
JP2012506856A (ja)	2008-10-28	2012-03-22	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
US8980891B2 (en)	2009-12-18	2015-03-17	Arena Pharmaceuticals, Inc.	Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2012149106A1 (en)	2011-04-29	2012-11-01	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for increasing proliferation of adult salivary stem cells
WO2013014204A2 (en)	2011-07-26	2013-01-31	Sanofi	3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
JP2018516992A (ja)	2015-06-12	2018-06-28	アクソファントサイエンシーズゲーエムベーハーＡｘｏｖａｎｔＳｃｉｅｎｃｅｓＧｍｂｈ	レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh)	2015-07-15	2018-08-31	阿速万科学有限责任公司	用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1250749B (it) *	1991-08-02	1995-04-21	Luso Farmaco Inst	Composti eterociclici ad attivita' a ii antagonista
DK41193D0 (da) *	1993-04-07	1993-04-07	Neurosearch As	Ionkanalaabnere
GB9401460D0 (en) *	1994-01-26	1994-03-23	Rhone Poulenc Rorer Ltd	Compositions of matter
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
US5780483A (en) *	1995-02-17	1998-07-14	Smithkline Beecham Corporation	IL-8 receptor antagonists
US6248713B1 (en) *	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
DE69706407T2 (de)	1996-03-29	2002-05-29	G.D. Searle & Co., Chicago	META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DK0891325T3 (da)	1996-03-29	2002-05-21	Searle & Co	Para-substituerede phenylpropansyrederivater som integrinantagonister
PL192628B1 (pl) *	1996-04-23	2006-11-30	Vertex Pharma	Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
WO1997049399A1 (en) *	1996-06-27	1997-12-31	Smithkline Beecham Corporation	Il-8 receptor antagonists
WO1997049400A1 (en) *	1996-06-27	1997-12-31	Smithkline Beecham Corporation	Il-8 receptor antagonists
JP2000516596A (ja)	1996-07-25	2000-12-12	バイオジェン，インコーポレイテッド	細胞接着インヒビター
CA2261974A1 (en) *	1996-07-25	1998-02-05	Biogen, Inc.	Molecular model for vla-4 inhibitors
US6352977B1 (en) *	1998-07-13	2002-03-05	Aventis Pharma Limited	Substituted β-alanines

1998
- 1998-11-02 DK DK98951596T patent/DK1027328T3/da active
- 1998-11-02 EP EP98951596A patent/EP1027328B1/en not_active Expired - Lifetime
- 1998-11-02 BR BR9813331-4A patent/BR9813331A/pt not_active Application Discontinuation
- 1998-11-02 KR KR1020007004600A patent/KR20010031557A/ko not_active Ceased
- 1998-11-02 SK SK546-2000A patent/SK5462000A3/sk unknown
- 1998-11-02 WO PCT/GB1998/003294 patent/WO1999023063A1/en not_active Ceased
- 1998-11-02 HU HU0100699A patent/HUP0100699A3/hu unknown
- 1998-11-02 PT PT98951596T patent/PT1027328E/pt unknown
- 1998-11-02 TR TR2000/01179T patent/TR200001179T2/xx unknown
- 1998-11-02 ES ES98951596T patent/ES2268793T3/es not_active Expired - Lifetime
- 1998-11-02 CN CN98812875A patent/CN1327443A/zh active Pending
- 1998-11-02 NZ NZ503407A patent/NZ503407A/xx unknown
- 1998-11-02 PL PL98340261A patent/PL340261A1/xx unknown
- 1998-11-02 IL IL13583698A patent/IL135836A0/xx active IP Right Grant
- 1998-11-02 AT AT98951596T patent/ATE337298T1/de active
- 1998-11-02 CA CA002303848A patent/CA2303848C/en not_active Expired - Lifetime
- 1998-11-02 DE DE69835688T patent/DE69835688T2/de not_active Expired - Lifetime
- 1998-11-02 AU AU97550/98A patent/AU748041B2/en not_active Expired
- 1998-11-02 JP JP2000518939A patent/JP4555468B2/ja not_active Expired - Lifetime
2000
- 2000-04-26 US US09/558,812 patent/US6479519B1/en not_active Expired - Lifetime
- 2000-04-27 IL IL135836A patent/IL135836A/en not_active IP Right Cessation
- 2000-04-28 NO NO20002276A patent/NO20002276L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2001521921A (ja)	2001-11-13
KR20010031557A (ko)	2001-04-16
EP1027328A1 (en)	2000-08-16
US6479519B1 (en)	2002-11-12
AU748041B2 (en)	2002-05-30
DE69835688T2 (de)	2007-10-04
ES2268793T3 (es)	2007-03-16
DK1027328T3 (da)	2006-11-13
ATE337298T1 (de)	2006-09-15
CA2303848C (en)	2008-09-30
DE69835688D1 (de)	2006-10-05
JP4555468B2 (ja)	2010-09-29
CA2303848A1 (en)	1999-05-14
CN1327443A (zh)	2001-12-19
NO20002276L (no)	2000-05-25
PT1027328E (pt)	2006-11-30
EP1027328B1 (en)	2006-08-23
HUP0100699A3 (en)	2002-11-28
NZ503407A (en)	2002-08-28
WO1999023063A1 (en)	1999-05-14
TR200001179T2 (tr)	2000-11-21
SK5462000A3 (en)	2001-02-12
BR9813331A (pt)	2000-08-22
PL340261A1 (en)	2001-01-29
IL135836A (en)	2006-12-10
IL135836A0 (en)	2001-05-20
HUP0100699A2 (hu)	2001-07-30
AU9755098A (en)	1999-05-24

Legal Events

Date	Code	Title	Description
2006-07-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DK1027328T3 (da)	2006-11-13	Substituerede anilider
TR200102959T2 (tr)	2002-04-22	İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
AP2003002841A0 (en)	2003-09-30	Quinazolines as MMP-13 inhibitors
DE60001229D1 (de)	2003-02-20	Triarylimidazole
DE60218454D1 (de)	2007-04-12	Biologisch aktive derivate des methylenblaus
TR200101744T2 (tr)	2001-12-21	Fenilglisin türevleri.
DK1204654T3 (da)	2003-11-17	Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
GR3033827T3 (en)	2000-10-31	New compounds and their compositions having anti-inflammatory and anti-thrombotic activities
ZA9710796B (en)	1998-06-12	Oxyiminopregnanecarbolactones.
DE60230127D1 (de)	2009-01-15	Inhibitoren von integrin alpha-v-beta-6
ATE289991T1 (de)	2005-03-15	Substituierte beta-alaninen
CY2198B1 (en)	2002-11-08	1-Aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
DK0954521T3 (da)	2003-09-15	4-[(thien-3-yl)methyl]-imidazoler med alfa2-adrenoceptor-agonistisk aktivitet
ES2196332T3 (es)	2003-12-16	Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos.
DE60121048D1 (de)	2006-08-03	PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DK1204659T3 (da)	2004-04-05	Serotonerge benzofuraner
IT1289979B1 (it)	1998-10-19	5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari
DE69816832D1 (de)	2003-09-04	Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
SE9603284D0 (sv)	1996-09-10	New compounds
DK0772620T3 (da)	2000-03-27	Anti-messenger-oligonucleotider og urokinase-recepter-reversion af den invasive fænotype af transformerede humane fibroblas
TR199902097A2 (xx)	2000-03-21	Mikrobial transformasyon.